Congress Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-102,698
| Closed | -$10.4M | – | 566 |
|
|
2023
Q1 | $10.4M | Buy |
102,698
+1,759
| +2% | +$178K | 0.25% | 126 |
|
|
2022
Q4 | $12.1M | Sell |
100,939
-8,774
| -8% | -$1.05M | 0.31% | 85 |
|
|
2022
Q3 | $11.7M | Buy |
109,713
+4,499
| +4% | +$478K | 0.31% | 78 |
|
|
2022
Q2 | $10.3M | Sell |
105,214
-416
| -0.4% | -$40.6K | 0.26% | 106 |
|
|
2022
Q1 | $9.9M | Buy |
105,630
+47,798
| +83% | +$4.48M | 0.22% | 140 |
|
|
2021
Q4 | $4.93M | Buy |
+57,832
| New | +$4.93M | 0.1% | 225 |
|